| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6827546 | Schizophrenia Research | 2011 | 6 Pages |
Abstract
Trial participants appeared to be representative of the 23.3% of VHA patients with schizophrenia who met the key trial inclusion criterion, suggesting that trial findings will be relevant to the broader group of high risk patients.
Keywords
Related Topics
Life Sciences
Neuroscience
Behavioral Neuroscience
Authors
Paul G. Barnett, Jennifer Y. Scott, Robert A. Rosenheck, for the CSP 555 Study Group for the CSP 555 Study Group,